Get the Stockscreener App
3.32
3.77%
-0.13
Agenus Inc stock is traded at $3.32, with a volume of 226.23K.
It is down -3.77% in the last 24 hours and down -13.32% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$3.45
Open:
$3.51
24h Volume:
226.23K
Relative Volume:
0.47
Market Cap:
$78.39M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0483
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-5.41%
1M Performance:
-13.32%
6M Performance:
-36.03%
1Y Performance:
-74.82%
1-Day Range:
$3.2701
$3.51
1-Week Range:
$3.2701
$3.60
52-Week Range:
$2.50
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.32 | 78.39M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Agenus, Inc. to Host Earnings Call - ACCESS Newswire
Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Business Wire
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Agenus reports promising sarcoma study results - MSN
Incyte Backs Out of Immuno-Oncology Pact With Agenus - BioSpace
Incyte exits immuno-oncology pact, leaving Agenus weighing options for assets - Fierce Biotech
Agenus IncIncyte To Terminate Agreement With Agenus Effective February 2026 - Marketscreener.com
Agenus Regains Rights to LAG-3 and TIM-3 Programs - TipRanks
Agenus Inc. and Incyte Corporation Provides Update on License, Development, and Commercialization Agreement - Marketscreener.com
Vaccine Adjuvants Market Next Big Thing | Major Giants- GlaxoSmithKline, Novavax, Agenus - openPR
AGEN Shareholders Have Opportunity to Lead Agenus Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts - Defense World
What is William Blair's Forecast for Agenus FY2024 Earnings? - MarketBeat
Reviewing Innate Pharma (NASDAQ:IPHA) and Agenus (NASDAQ:AGEN) - Defense World
FY2024 Earnings Forecast for Agenus Issued By William Blair - Defense World
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development - NewsBreak
Agenus reports publication of data from bot/bal combination in JOCO - TipRanks
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas | Business Wire - businesswire.fr
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data - Endpoints News
Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright - Defense World
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewswire Inc.
Agenus reports promising colorectal cancer treatment data - MSN
Barclays PLC Buys 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease - BioSpace
Agenus reports promising colorectal cancer treatment data By Investing.com - Investing.com UK
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - Morningstar
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Cervical Cancer Market Expected to Experience Major Growth - openPR
What Makes Agenus (AGEN) a New Buy Stock - Yahoo Finance
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Stock Holdings Lessened by Jane Street Group LLC - Defense World
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Analysts - MarketBeat
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease - GlobeNewswire
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease Type, VaccineGlobal Forecast to 2029 with GSK, Seppic, Croda, SPI Pharma, Phibro Animal Health, Agenus, Dynavax Technologies Dominating - Yahoo Finance UK
Barclays PLC Purchases 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
State Street Corp Boosts Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus Inc. (NASDAQ:AGEN) Short Interest Up 6.5% in December - Defense World
HighTower Advisors LLC Boosts Holdings in Agenus Inc. (NASDAQ:AGEN) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - The Eastern Progress Online
AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Invest - GuruFocus.com
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Inve - GuruFocus.com
Agenus (AGEN) Stock Surges Amid Positive Market Movement - GuruFocus.com
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers - Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
BNP Paribas Financial Markets Acquires 37,866 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus (AGEN) Stock Plummets 5.08% Amidst Mixed Ratings - GuruFocus.com
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):